Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JUVÉDERM VOLUX · 1 trial · 1 indication
The G-Sn-Pog angle is the angle formed by the point on the glabella, subnasale, and pogonion.
| Arm | Type | Description |
|---|---|---|
| JUVÉDERM VOLUX® | EXPERIMENTAL | Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional touch-up treatment at week 4 if agreed upon by both the participant and Treating Investigator. |
| Control- No treatment | OTHER | No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period. |
| Name | Type | Description |
|---|---|---|
| JUVÉDERM VOLUX® | DEVICE | JUVÉDERM VOLUX® injectable gel |
Inclusion Criteria: * Participant must be at least 18 years of age at the time of signing the ICF * Male and female * Participants of Chinese descent * Participants seeking improvement of chin retrusion * Chin retrusion (G-Sn-Pog angle of \< 172.5°) based on calculations of facial angle derived fro...
JUVÉDERM VOLUX is an investigational product being studied for the treatment of chin retrusion, a condition where the chin is set back relative to the rest of the face. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
JUVÉDERM VOLUX is developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The product is part of the JUVÉDERM family of dermal fillers, though it is specifically being studied for chin augmentation.
JUVÉDERM VOLUX is in Phase 3 clinical development for chin retrusion. It is an investigational product, meaning it has not yet received regulatory approval and is still undergoing clinical trials to evaluate its safety and efficacy.
JUVÉDERM VOLUX has one completed Phase 3 clinical trial, identified by the National Clinical Trial number NCT04559984. This trial, titled 'JUVÉDERM VOLUX® for Chin Retrusion in China,' enrolled 150 participants aged 18 years and older in China. The study was controlled but not double-blinded.
JUVÉDERM VOLUX is not FDA approved. It is an investigational product currently in Phase 3 clinical development for chin retrusion. Regulatory approval has not been granted, and the product remains under study to determine its safety and effectiveness.